Wall Street brokerages forecast that Matinas Biopharma Holdings, Inc. (NASDAQ:MTNB) will announce earnings per share (EPS) of ($0.04) for the current quarter, Zacks reports. Two analysts have made estimates for Matinas Biopharma’s earnings. The lowest EPS estimate is ($0.04) and the highest is ($0.03). Matinas Biopharma also reported earnings of ($0.04) per share during the same quarter last year. The firm is expected to announce its next earnings results before the market opens on Tuesday, August 13th.
According to Zacks, analysts expect that Matinas Biopharma will report full-year earnings of ($0.15) per share for the current year, with EPS estimates ranging from ($0.17) to ($0.13). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.17) per share, with EPS estimates ranging from ($0.20) to ($0.14). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Matinas Biopharma.
Matinas Biopharma (NASDAQ:MTNB) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01).
Separately, HC Wainwright reissued a “buy” rating on shares of Matinas Biopharma in a report on Wednesday, June 26th.
Shares of NASDAQ MTNB traded up $0.06 during midday trading on Tuesday, reaching $0.71. 915,500 shares of the stock were exchanged, compared to its average volume of 933,134. Matinas Biopharma has a twelve month low of $0.35 and a twelve month high of $1.50. The firm has a 50-day moving average price of $0.79.
About Matinas Biopharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Featured Story: What is the Russell 2000 Index?
Get a free copy of the Zacks research report on Matinas Biopharma (MTNB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.